0001415889-24-018162.txt : 20240625
0001415889-24-018162.hdr.sgml : 20240625
20240625174538
ACCESSION NUMBER: 0001415889-24-018162
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240620
FILED AS OF DATE: 20240625
DATE AS OF CHANGE: 20240625
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cui Xiangmin
CENTRAL INDEX KEY: 0001487815
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39351
FILM NUMBER: 241070106
MAIL ADDRESS:
STREET 1: NO. 14 EAST HUSHAN ROAD
STREET 2: TAI'AN CITY
CITY: SHANDONG
STATE: F4
ZIP: 000000
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nuvation Bio Inc.
CENTRAL INDEX KEY: 0001811063
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 850862255
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 357 TEHAMA STREET, FLOOR 3
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94103
BUSINESS PHONE: (415) 754-3517
MAIL ADDRESS:
STREET 1: 357 TEHAMA STREET, FLOOR 3
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94103
FORMER COMPANY:
FORMER CONFORMED NAME: Panacea Acquisition Corp
DATE OF NAME CHANGE: 20200430
4
1
form4-06252024_090633.xml
X0508
4
2024-06-20
0001811063
Nuvation Bio Inc.
NUVB
0001487815
Cui Xiangmin
C/O NUVATION BIO INC.
1500 BROADWAY, SUITE 1401
NEW YORK
NY
10036
true
false
false
false
0
Class A Common Stock
2024-06-20
4
P
0
87715
2.99
A
1762951
I
By Decheng Capital Global Healthcare Fund (Master), LP
Class A Common Stock
2024-06-21
4
P
0
75411
3
A
1838362
I
By Decheng Capital Global Healthcare Fund (Master), LP
Class A Common Stock
2024-06-24
4
P
0
336874
2.98
A
2175236
I
By Decheng Capital Global Healthcare Fund (Master), LP
Class A Common Stock
314106
I
By Decheng Capital China Life Sciences USD Fund III, L.P.
Class A Common Stock
4183002
I
By Decheng Anbio Limited
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.90 to $3.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). The Reporting Person is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.99 to $3.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.93 to $3.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
These securities are owned directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). The Reporting Person is the manager of Decheng Capital Management III (Cayman), LLC, the general partner of Fund III. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
These securities are owned directly by Decheng Anbio Limited ("SPV"). The Reporting Person is a director of SPV. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
/s/ Xiangmin Cui
2024-06-25